JP2010063458A5 - - Google Patents

Download PDF

Info

Publication number
JP2010063458A5
JP2010063458A5 JP2009239422A JP2009239422A JP2010063458A5 JP 2010063458 A5 JP2010063458 A5 JP 2010063458A5 JP 2009239422 A JP2009239422 A JP 2009239422A JP 2009239422 A JP2009239422 A JP 2009239422A JP 2010063458 A5 JP2010063458 A5 JP 2010063458A5
Authority
JP
Japan
Prior art keywords
breast cancer
gated
voltage
compound
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009239422A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010063458A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2010063458A publication Critical patent/JP2010063458A/ja
Publication of JP2010063458A5 publication Critical patent/JP2010063458A5/ja
Pending legal-status Critical Current

Links

JP2009239422A 2001-04-12 2009-10-16 Ｉ型癌の診断および治療 Pending JP2010063458A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28329501P 2001-04-12 2001-04-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2002582281A Division JP4541645B2 (ja) 2001-04-12 2002-04-11 Ｉ型癌の診断および治療

Publications (2)

Publication Number Publication Date
JP2010063458A JP2010063458A (ja) 2010-03-25
JP2010063458A5 true JP2010063458A5 (cg-RX-API-DMAC7.html) 2011-08-11

Family

ID=23085371

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002582281A Expired - Fee Related JP4541645B2 (ja) 2001-04-12 2002-04-11 Ｉ型癌の診断および治療
JP2009239422A Pending JP2010063458A (ja) 2001-04-12 2009-10-16 Ｉ型癌の診断および治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2002582281A Expired - Fee Related JP4541645B2 (ja) 2001-04-12 2002-04-11 Ｉ型癌の診断および治療

Country Status (7)

Country Link
US (3) US7393657B2 (cg-RX-API-DMAC7.html)
EP (2) EP1377680B1 (cg-RX-API-DMAC7.html)
JP (2) JP4541645B2 (cg-RX-API-DMAC7.html)
AT (1) ATE527375T1 (cg-RX-API-DMAC7.html)
AU (3) AU2002244862B2 (cg-RX-API-DMAC7.html)
CA (1) CA2443968A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002083945A2 (cg-RX-API-DMAC7.html)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300108B1 (en) * 1999-07-21 2001-10-09 The Regents Of The University Of California Controlled electroporation and mass transfer across cell membranes
US6795728B2 (en) 2001-08-17 2004-09-21 Minnesota Medical Physics, Llc Apparatus and method for reducing subcutaneous fat deposits by electroporation
US6892099B2 (en) 2001-02-08 2005-05-10 Minnesota Medical Physics, Llc Apparatus and method for reducing subcutaneous fat deposits, virtual face lift and body sculpturing by electroporation
US6697670B2 (en) 2001-08-17 2004-02-24 Minnesota Medical Physics, Llc Apparatus and method for reducing subcutaneous fat deposits by electroporation with improved comfort of patients
US8251986B2 (en) * 2000-08-17 2012-08-28 Angiodynamics, Inc. Method of destroying tissue cells by eletroporation
US6994706B2 (en) * 2001-08-13 2006-02-07 Minnesota Medical Physics, Llc Apparatus and method for treatment of benign prostatic hyperplasia
US7130697B2 (en) * 2002-08-13 2006-10-31 Minnesota Medical Physics Llc Apparatus and method for the treatment of benign prostatic hyperplasia
USRE42016E1 (en) 2001-08-13 2010-12-28 Angiodynamics, Inc. Apparatus and method for the treatment of benign prostatic hyperplasia
US9278088B2 (en) 2002-02-19 2016-03-08 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
US7659082B2 (en) * 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
ES2543832T3 (es) 2003-12-24 2015-08-24 The Regents Of The University Of California Ablación de tejido con electroporación irreversible
US8298222B2 (en) 2003-12-24 2012-10-30 The Regents Of The University Of California Electroporation to deliver chemotherapeutics and enhance tumor regression
CA2553745A1 (en) * 2004-01-21 2005-08-04 University Of Utah Research Foundation Mutant sodium channel nav1.7 and methods related thereto
JP4443278B2 (ja) * 2004-03-26 2010-03-31 テルモ株式会社 拡張体付カテーテル
US20060264752A1 (en) * 2005-04-27 2006-11-23 The Regents Of The University Of California Electroporation controlled with real time imaging
US20060293725A1 (en) * 2005-06-24 2006-12-28 Boris Rubinsky Methods and systems for treating fatty tissue sites using electroporation
US20060293731A1 (en) * 2005-06-24 2006-12-28 Boris Rubinsky Methods and systems for treating tumors using electroporation
US20060293730A1 (en) 2005-06-24 2006-12-28 Boris Rubinsky Methods and systems for treating restenosis sites using electroporation
US8114070B2 (en) * 2005-06-24 2012-02-14 Angiodynamics, Inc. Methods and systems for treating BPH using electroporation
US20070156135A1 (en) * 2006-01-03 2007-07-05 Boris Rubinsky System and methods for treating atrial fibrillation using electroporation
WO2008048620A2 (en) 2006-10-16 2008-04-24 The Regents Of The University Of California Gels with predetermined conductivity used in irreversible electroporation of tissue
US20080132885A1 (en) * 2006-12-01 2008-06-05 Boris Rubinsky Methods for treating tissue sites using electroporation
US20080132884A1 (en) * 2006-12-01 2008-06-05 Boris Rubinsky Systems for treating tissue sites using electroporation
JP2010540534A (ja) 2007-09-28 2010-12-24 イントレキソン コーポレーション 生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用
US8563695B2 (en) * 2007-11-19 2013-10-22 Genentech, Inc. Antibodies that bind β2
EP2093567A1 (en) * 2008-02-21 2009-08-26 Pangaea Biotech, S.A. Brca1 mRNA expression levels predict survival in breast cancer patients treated with neoadjuvant chemotherapy
WO2009121009A2 (en) 2008-03-27 2009-10-01 The Regents Of The University Of California Irreversible electroporation device for use in attenuating neointimal
US20100004623A1 (en) * 2008-03-27 2010-01-07 Angiodynamics, Inc. Method for Treatment of Complications Associated with Arteriovenous Grafts and Fistulas Using Electroporation
US10245098B2 (en) 2008-04-29 2019-04-02 Virginia Tech Intellectual Properties, Inc. Acute blood-brain barrier disruption using electrical energy based therapy
US11254926B2 (en) 2008-04-29 2022-02-22 Virginia Tech Intellectual Properties, Inc. Devices and methods for high frequency electroporation
US10238447B2 (en) 2008-04-29 2019-03-26 Virginia Tech Intellectual Properties, Inc. System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress
US8992517B2 (en) 2008-04-29 2015-03-31 Virginia Tech Intellectual Properties Inc. Irreversible electroporation to treat aberrant cell masses
US9867652B2 (en) 2008-04-29 2018-01-16 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
US10272178B2 (en) 2008-04-29 2019-04-30 Virginia Tech Intellectual Properties Inc. Methods for blood-brain barrier disruption using electrical energy
CA2722296A1 (en) 2008-04-29 2009-11-05 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation to create tissue scaffolds
US10702326B2 (en) 2011-07-15 2020-07-07 Virginia Tech Intellectual Properties, Inc. Device and method for electroporation based treatment of stenosis of a tubular body part
US9198733B2 (en) 2008-04-29 2015-12-01 Virginia Tech Intellectual Properties, Inc. Treatment planning for electroporation-based therapies
US10117707B2 (en) 2008-04-29 2018-11-06 Virginia Tech Intellectual Properties, Inc. System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
US9283051B2 (en) 2008-04-29 2016-03-15 Virginia Tech Intellectual Properties, Inc. System and method for estimating a treatment volume for administering electrical-energy based therapies
US11272979B2 (en) 2008-04-29 2022-03-15 Virginia Tech Intellectual Properties, Inc. System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
US20090281477A1 (en) * 2008-05-09 2009-11-12 Angiodynamics, Inc. Electroporation device and method
US9173704B2 (en) * 2008-06-20 2015-11-03 Angiodynamics, Inc. Device and method for the ablation of fibrin sheath formation on a venous catheter
US9681909B2 (en) * 2008-06-23 2017-06-20 Angiodynamics, Inc. Treatment devices and methods
US20100152725A1 (en) * 2008-12-12 2010-06-17 Angiodynamics, Inc. Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation
WO2010085765A2 (en) * 2009-01-23 2010-07-29 Moshe Meir H Therapeutic energy delivery device with rotational mechanism
US8231603B2 (en) * 2009-02-10 2012-07-31 Angiodynamics, Inc. Irreversible electroporation and tissue regeneration
US8632534B2 (en) 2009-04-03 2014-01-21 Angiodynamics, Inc. Irreversible electroporation (IRE) for congestive obstructive pulmonary disease (COPD)
US11382681B2 (en) 2009-04-09 2022-07-12 Virginia Tech Intellectual Properties, Inc. Device and methods for delivery of high frequency electrical pulses for non-thermal ablation
WO2010118387A1 (en) * 2009-04-09 2010-10-14 Virginia Tech Intellectual Properties, Inc. Integration of very short electric pulses for minimally to noninvasive electroporation
US11638603B2 (en) 2009-04-09 2023-05-02 Virginia Tech Intellectual Properties, Inc. Selective modulation of intracellular effects of cells using pulsed electric fields
USD630321S1 (en) 2009-05-08 2011-01-04 Angio Dynamics, Inc. Probe handle
US8903488B2 (en) 2009-05-28 2014-12-02 Angiodynamics, Inc. System and method for synchronizing energy delivery to the cardiac rhythm
US9895189B2 (en) 2009-06-19 2018-02-20 Angiodynamics, Inc. Methods of sterilization and treating infection using irreversible electroporation
US20120283116A1 (en) 2009-09-11 2012-11-08 Leppert Mark F Mutant Sodium Channel Nav1.7 and Methods Related Thereto
US20110118732A1 (en) 2009-11-19 2011-05-19 The Regents Of The University Of California Controlled irreversible electroporation
PL2585596T3 (pl) * 2010-06-23 2021-06-28 Curna, Inc. Leczenie chorób związanych z podjednostką alfa kanału sodowego bramkowanego napięciem (SCNA) poprzez hamowanie naturalnego transkryptu antysensownego SCNA
EP2627274B1 (en) 2010-10-13 2022-12-14 AngioDynamics, Inc. System for electrically ablating tissue of a patient
WO2012088149A2 (en) 2010-12-20 2012-06-28 Virginia Tech Intellectual Properties, Inc. High-frequency electroporation for cancer therapy
HK1198173A1 (en) 2011-03-16 2015-03-13 Amgen Inc. Potent and selective inhibitors of nav1.3 and nav1.7
EP2734214B1 (en) 2011-07-21 2019-05-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Targeted osmotic lysis of cancer cells
US9078665B2 (en) 2011-09-28 2015-07-14 Angiodynamics, Inc. Multiple treatment zone ablation probe
ITMO20120015A1 (it) * 2012-01-26 2013-07-27 Guescini Michele Proprieta Al 25 Metodo di perfezionamento per la determinazione quantitativa degli acidi nucleici
US9414881B2 (en) 2012-02-08 2016-08-16 Angiodynamics, Inc. System and method for increasing a target zone for electrical ablation
US9888956B2 (en) 2013-01-22 2018-02-13 Angiodynamics, Inc. Integrated pump and generator device and method of use
AR096927A1 (es) 2013-03-12 2016-02-10 Amgen Inc INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
TW201446792A (zh) 2013-03-12 2014-12-16 Amgen Inc Nav1．7之強效及選擇性抑制劑
US10166321B2 (en) 2014-01-09 2019-01-01 Angiodynamics, Inc. High-flow port and infusion needle systems
ES3010493T3 (en) 2014-05-12 2025-04-03 Virginia Tech Intellectual Properties Inc Selective modulation of intracellular effects of cells using pulsed electric fields
US12114911B2 (en) 2014-08-28 2024-10-15 Angiodynamics, Inc. System and method for ablating a tissue site by electroporation with real-time pulse monitoring
WO2016100325A1 (en) 2014-12-15 2016-06-23 Virginia Tech Intellectual Properties, Inc. Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment
US10660691B2 (en) 2015-10-07 2020-05-26 Angiodynamics, Inc. Multiple use subassembly with integrated fluid delivery system for use with single or dual-lumen peristaltic tubing
US10905492B2 (en) 2016-11-17 2021-02-02 Angiodynamics, Inc. Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode
EP3654841B1 (en) 2017-07-20 2024-02-07 Board Of Supervisors Of Louisiana State University Targeted osmotic lysis of malignant cancer cells using pulsed magnetic field gradients
US11607537B2 (en) 2017-12-05 2023-03-21 Virginia Tech Intellectual Properties, Inc. Method for treating neurological disorders, including tumors, with electroporation
US11925405B2 (en) 2018-03-13 2024-03-12 Virginia Tech Intellectual Properties, Inc. Treatment planning system for immunotherapy enhancement via non-thermal ablation
US12390262B2 (en) 2018-03-13 2025-08-19 Virginia Tech Intellectual Properties, Inc. Treatment planning system for immunotherapy enhancement via non-thermal ablation
US11311329B2 (en) 2018-03-13 2022-04-26 Virginia Tech Intellectual Properties, Inc. Treatment planning for immunotherapy based treatments using non-thermal ablation techniques
SG11202012161RA (en) 2018-06-22 2021-01-28 Hoffmann La Roche Oligonucleotides for modulating scn9a expression
US11950835B2 (en) 2019-06-28 2024-04-09 Virginia Tech Intellectual Properties, Inc. Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy
US12214189B2 (en) 2019-07-24 2025-02-04 Virginia Tech Intellectual Properties, Inc. Fourier analysis spectroscopy for monitoring tissue impedance changes and treatment outcome during electroporation-based-therapies
AR120817A1 (es) 2019-12-20 2022-03-23 Hoffmann La Roche Oligonucleótidos mejorados para inhibir la expresión de scn9a
US12485279B2 (en) 2020-11-25 2025-12-02 Virginia Tech Intellectual Properties, Inc. Methods for modulating temporal infrastructure of pulsed electric fields
USD1084316S1 (en) 2023-11-20 2025-07-15 Angiodynamics, Inc. Ferrule

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5149796A (en) 1989-08-31 1992-09-22 City Of Hope Chimeric DNA-RNA catalytic sequences
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
US5541104A (en) 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
PT658113E (pt) 1992-08-31 2005-03-31 Ludwig Inst Cancer Res Nonapeptideo isolado derivado do gene mage-3 e apresentado por hla-a1, e utilizacoes deste
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
DE69524264T2 (de) 1994-03-01 2002-07-18 Ludwig Institute For Cancer Research, New York Bestimmung krebsartiger beschaffenheiten durch die genexpression eines mitgliedes der melanomartigengruppe, mage
WO1996006641A1 (en) 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
US5599673A (en) * 1995-03-09 1997-02-04 University Of Utah Research Foundation Long QT syndrome genes
US5859699A (en) 1997-02-07 1999-01-12 Arcturus Engineering, Inc. Laser capture microdissection analysis vessel
US7312043B2 (en) * 2000-07-10 2007-12-25 Vertex Pharmaceuticals (San Diego) Llc Ion channel assay methods
GB0021617D0 (en) 2000-09-02 2000-10-18 Imp College Innovations Ltd Diagnosis and treatment of cancer

Similar Documents

Publication Publication Date Title
JP2010063458A5 (cg-RX-API-DMAC7.html)
KR20200103018A (ko) Gpcr 헤테로머 억제제 및 이의 용도
CN110199032A (zh) 羟基类固醇17-β脱氢酶13(HSD17B13)变体及其用途
AU2017343779A1 (en) Compositions and methods for predicting response and resistance to CTLA4 blockade in melanoma using a gene expression signature
JP2013178260A5 (cg-RX-API-DMAC7.html)
JP2008537546A5 (cg-RX-API-DMAC7.html)
JP7271446B2 (ja) Ｈｌａ－ｇ転写物およびアイソフォームおよびそれらの使用
JP2017506623A5 (cg-RX-API-DMAC7.html)
CN107602690B (zh) 肺动脉高压相关的ptgis基因突变及其应用
JP2008508861A5 (cg-RX-API-DMAC7.html)
KR20070092737A (ko) 임신 합병증의 진단 및 치료에 유용한 핵산 및 폴리펩티드
JP2011518773A5 (cg-RX-API-DMAC7.html)
JP2007521015A5 (cg-RX-API-DMAC7.html)
JP2014503180A5 (cg-RX-API-DMAC7.html)
KR20140016230A (ko) 암의 진단 및 치료를 위한 방법 및 화합물
US20190256930A1 (en) Biomarkers for determining responsiveness to lsd1 inhibitors
JP2005519608A5 (cg-RX-API-DMAC7.html)
JP2009536526A5 (cg-RX-API-DMAC7.html)
ES2272309T3 (es) 15571, una nueva molecula de tipo gpcr de la familia de tipo secretina y sus usos.
CA2506737A1 (en) Methods and kits for diagnosing and treating b-cell chronic lymphocytic leukemia (b-cll)
WO2022022541A1 (zh) Rbm10基因的用途
US8263822B2 (en) TREM-2 gene and protein as inhibitors of expression of GA733-2, and transgenic animals comprising the same and uses thereof
KR20190083110A (ko) 마약 중독 또는 금단증상 진단용 바이오마커 조성물 및 마약 중독 또는 금단증상 진단용 키트
JP2007077155A5 (cg-RX-API-DMAC7.html)
WO2011134420A1 (en) Detection and modulation of slit and roundabount (robo) mediated lymph vessel formation and uses thereof